Cargando...
Bispecific antibodies in cancer immunotherapy
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeu...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publishing
2018-02-01
|
| Colección: | Therapeutic Advances in Vaccines and Immunotherapy |
| Acceso en línea: | https://doi.org/10.1177/2515135518763280 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|